Dsm‐5 and the ‘psychosis risk syndrome’: Eight reasons to reject it

Psychosis

Volumn 2, Issue 2, 2010, Pages 107-110

  Ross, Colin A ^a  

^a Institute for Psychological Trauma   (United States)

Author keywords

Dsm 5; Psychopharmacology; Psychosis risk syndrome

Indexed keywords

EID: 78650922567     PISSN: 17522439     EISSN: 17522447     Source Type: Journal    
DOI: 10.1080/17522431003763323     Document Type: Article

References (5)

1. Lieberman, J.A., Stroup, T.R., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, P.H.C., Lebowitz, B.D., Severe, J., & Hsiao, J.K. (2005). Effectiveness of antipsychotics in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
2. Pathak, P., West, D., Martin, B., Helm, M., & Henderson, C. (2010). Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001-2005. Psychiatric Services, 61, 123–129.
3. Ross, C.A, (2004). Schizophrenia: Innovations in diagnosis and treatment. New York: Haworth.
4. Ross, C.A. (2005). A proposed trial of dialectical behavior therapy and trauma model therapy. Psychological Reports, 96, 901-911. www.dsm5.org/Proposed Revisions/Pages/proposed revision.aspx?rid=412
5. Weinmann, S., & Aderhold, V. (2010). Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis: Psychological, Social and Integrative Approaches, 2(1), 50–69.